14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
BMED vs LSAT: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, iShares Health Innovation Active ETF (BMED) is the stronger overall head-to-head candidate over LeaderShares AlphaFactor Tactical Focused ETF (LSAT) in the Tradestie Institutional Equity Comparison Engine, winning 1–2 core matrix metrics and 0–0 across our 6-pillar institutional scorecard (led by composite factor balance). BMED carries a Unified Composite Score of 51.8/100 (HOLD) at $35.93 (N/M Forward P/E, N/A operating margin), whereas LSAT carries 42.3/100 (HOLD) at $48.45 (N/M Forward P/E, N/A operating margin).
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on BMED vs LSAT. Trailing 12-month operating profitability (BMED N/A vs LSAT N/A) and valuation multiples (BMED N/M vs LSAT N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ BMED vs LSAT Key Questions & Quantitative Answers
As of Nov 16, 2026, iShares Health Innovation Active ETF (BMED) is the stronger overall head-to-head candidate over LeaderShares AlphaFactor Tactical Focused ETF (LSAT) in the Tradestie Institutional Equity Comparison Engine, winning 1–2 core matrix metrics and 0–0 across our 6-pillar institutional scorecard (led by composite factor balance). BMED carries a Unified Composite Score of 51.8/100 (HOLD) at $35.93 (N/M Forward P/E, N/A operating margin), whereas LSAT carries 42.3/100 (HOLD) at $48.45 (N/M Forward P/E, N/A operating margin). Technically, BMED sits in a Markup phase (RSI 50.9, UNCLASSIFIED options structure) and LSAT sits in a Markup phase (RSI 54.4, UNCLASSIFIED options structure).
BMED and LSAT split Growth & Scale metrics: BMED posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with LSAT at N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin). On trailing 12-month operating scale, BMED generates N/A in USD-normalized revenue versus N/A for LSAT. In operating R&D and SG&A reinvestment, BMED deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for LSAT.
BMED and LSAT trade at balanced relative valuation multiples. BMED trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas LSAT trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against BMED (N/A ROE) versus LSAT (N/A ROE) capital efficiency.
In options market volatility and institutional positioning, BMED carries 42.3% implied volatility (100th %ile, Extreme (>80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.61β · 24% Vol realized risk). By comparison, LSAT carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.41β · 20% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.